Could a single infusion keep High-Risk leukemia in check?
NCT ID NCT07053059
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 29 times
Summary
This phase 2 trial tests whether a CAR T-cell therapy called obecabtagene autoleucel (obe-cel) can help control high-risk B-cell acute lymphoblastic leukemia (ALL) after initial treatment. The study enrolls 30 adults with newly diagnosed high-risk ALL who are in first remission. Obe-cel is given as a single infusion to try to prevent the cancer from coming back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOCYTIC LEUKEMIA (ALL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University of Texas M. D. Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
obecabtagene autoleucel (a type of CAR T-cell therapy)
What this could lead to
If successful, this could offer a more effective way to prevent relapse in people with high-risk B-cell acute lymphoblastic leukemia after initial treatment.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. CAR T-cell therapy can cause serious side effects like cytokine release syndrome or nervous system problems.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.